Evidence map›Paper›PMID 39220887›Full record

ArticleActa pharmaceutica Sinica. B2024

CCL9/CCR1 axis-driven chemotactic nanovesicles for attenuating metastasis of SMAD4-deficient colorectal cancer by trapping TGF-

Boning Niu, Tianyi Tian, Lu Wang, Yinmei Tian, Tian Tian, Yuanyuan Guo, Hu Zhou, Zhiping Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Article
  3. B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Boning NiuTongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, China.
Tianyi TianTongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, China.
Lu WangDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Yinmei TianTongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, China.
Tian TianTongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, China.
Yuanyuan GuoDepartment of Pharmacy, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Hu ZhouSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, High Throughput Drug Screening Platform, Xiamen University, Xiamen 361102, China.
Zhiping ZhangTongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SMAD4 deficiency in colorectal cancer (CRC) is highly correlated with liver metastasis and high mortality, yet there are few effective precision therapies available. Here, we show that CCR1

Indexed as

CCR1Chemotactic nanovesiclesG-MDSCsMetastasisSMAD4-deficient CRCTertiary lymphoid structuresTGFBR2TGF-β

Identifiers

PMID39220887
PMCPMC11365421

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.